Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression
IntroductionIntranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry.MethodsThis cas...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1536232/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849404614924828672 |
|---|---|
| author | Alexandre Fraichot Sophie Favre Hélène Richard-Lepouriel Hélène Richard-Lepouriel |
| author_facet | Alexandre Fraichot Sophie Favre Hélène Richard-Lepouriel Hélène Richard-Lepouriel |
| author_sort | Alexandre Fraichot |
| collection | DOAJ |
| description | IntroductionIntranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry.MethodsThis case report presents the outcome of a 37-year-old patient who received intranasal Esketamine treatment (84 mg) and utilized artificial intelligence (ChatGPT-4) to generate images and interpretations of his experiences with dissociation. This process was conducted in the presence of a nurse who assessed and supported the patient. The Montgomery–Åsberg Depression Rating Scale (MADRS) was used to measure the severity of depression at the beginning of each session.ResultsThe patient achieved remission from depression, with MADRS scores declining by 50% in the third session, and the scores indicated mild depression or euthymia in the eight subsequent sessions. The patient reported that incorporating artificial intelligence-generated images and interpretations helped him create a timeline of his experiences at the end of each session.DiscussionThis case report highlights the potential effectiveness of combining intranasal Esketamine treatment with generative artificial intelligence images and interpretations as part of an integration process. It also emphasizes the importance of having a nurse present to support the process. Further research is needed to determine which patients may benefit most from this combined treatment approach. |
| format | Article |
| id | doaj-art-7baa582473e047219324b0683cd052f2 |
| institution | Kabale University |
| issn | 1664-0640 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj-art-7baa582473e047219324b0683cd052f22025-08-20T03:36:57ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402025-08-011610.3389/fpsyt.2025.15362321536232Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depressionAlexandre Fraichot0Sophie Favre1Hélène Richard-Lepouriel2Hélène Richard-Lepouriel3Mood and Anxiety Disorder Unit, Psychiatric Specialties Service, Department of Psychiatry, Geneva University Hospital, Geneva, SwitzerlandMood and Anxiety Disorder Unit, Psychiatric Specialties Service, Department of Psychiatry, Geneva University Hospital, Geneva, SwitzerlandMood and Anxiety Disorder Unit, Psychiatric Specialties Service, Department of Psychiatry, Geneva University Hospital, Geneva, SwitzerlandDepartment of Psychiatry, University of Geneva, Geneva, SwitzerlandIntroductionIntranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry.MethodsThis case report presents the outcome of a 37-year-old patient who received intranasal Esketamine treatment (84 mg) and utilized artificial intelligence (ChatGPT-4) to generate images and interpretations of his experiences with dissociation. This process was conducted in the presence of a nurse who assessed and supported the patient. The Montgomery–Åsberg Depression Rating Scale (MADRS) was used to measure the severity of depression at the beginning of each session.ResultsThe patient achieved remission from depression, with MADRS scores declining by 50% in the third session, and the scores indicated mild depression or euthymia in the eight subsequent sessions. The patient reported that incorporating artificial intelligence-generated images and interpretations helped him create a timeline of his experiences at the end of each session.DiscussionThis case report highlights the potential effectiveness of combining intranasal Esketamine treatment with generative artificial intelligence images and interpretations as part of an integration process. It also emphasizes the importance of having a nurse present to support the process. Further research is needed to determine which patients may benefit most from this combined treatment approach.https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1536232/fullintranasal esketamineartificial intelligencetreatment-resistant depressioncase reportdepression |
| spellingShingle | Alexandre Fraichot Sophie Favre Hélène Richard-Lepouriel Hélène Richard-Lepouriel Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression Frontiers in Psychiatry intranasal esketamine artificial intelligence treatment-resistant depression case report depression |
| title | Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression |
| title_full | Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression |
| title_fullStr | Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression |
| title_full_unstemmed | Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression |
| title_short | Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression |
| title_sort | case report intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment resistant depression |
| topic | intranasal esketamine artificial intelligence treatment-resistant depression case report depression |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1536232/full |
| work_keys_str_mv | AT alexandrefraichot casereportintranasalesketaminecombinedwithaformofgenerativeartificialintelligenceinthemanagementoftreatmentresistantdepression AT sophiefavre casereportintranasalesketaminecombinedwithaformofgenerativeartificialintelligenceinthemanagementoftreatmentresistantdepression AT helenerichardlepouriel casereportintranasalesketaminecombinedwithaformofgenerativeartificialintelligenceinthemanagementoftreatmentresistantdepression AT helenerichardlepouriel casereportintranasalesketaminecombinedwithaformofgenerativeartificialintelligenceinthemanagementoftreatmentresistantdepression |